<DOC>
	<DOCNO>NCT03058406</DOCNO>
	<brief_summary>The purpose study understand safety efficacy participant soft tissue sarcoma .</brief_summary>
	<brief_title>A Study Safety Efficacy Patients With Soft Tissue Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Participants soft tissue sarcoma receive eribulin mesylate per approve indication routine clinical practice None</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sarcoma , Soft Tissue</keyword>
	<keyword>Halaven Injection</keyword>
	<keyword>E7389</keyword>
</DOC>